← BioTransfer GEO Dataset Finder
GEO series

Fatty acid synthesis therapy-induced senescence (FASTIS) in cancer cells

GSE292003 Homo sapiens (human) RNA-seq (gene expression) 24 samples Submitted 2026/03/14 Platform GPL24676
At a glance

RNA-seq (gene expression) · human · 24 samples

What it is
RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism
Homo sapiens (human)
Samples
24 samples: 8 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
Data you can get
A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Paper
Fatty acid synthesis therapy-induced senescence (FASTIS) in cancer cellsCell death & disease · 2026
Summary (written by the submitters)
Conventional chemotherapeutic agents and radiation induce accelerated senescence in cancer cells, a phenomenon known as therapy- induced senescence (TIS). Here, we investigated whether TIS can also be induced by targeted inhibition of de novo lipogenesis, which we term fatty acid synthesis therapy-induced senescence (FASTIS).
Read the full summary ↓
SKBR3 breast cancer cells were treated for 7 days with clinically relevant inhibitors of the key lipogenic enzymes acetyl-CoA carboxylase (ND-646) and fatty acid synthase (TVB-3166) as well as with the well-established, mechanistically distinct TIS inducers bleomycin (an antibiotic that promotes oxidative stress), alisertib (an Aurora A kinase inhibitor that promotes mitotic stress), doxorubicin (a topoisomerase II inhibitor and DNA intercalator that induces DNA damage stress), and palbociclib (a CDK4/6 inhibitor that induces replication stress). To understand the unique versus shared molecular changes of the FASTIS phenotype induced by fatty acid synthesis inhibitors compared to other TIS inducers, we performed mRNA-Seq experiments to provide a comprehensive, high-resolution view of the underlying coding transcriptomes. To account for potential artifacts due to cell subpopulations entering a quiescent state to survive nutrient deprivation after 7 days, parallel mRNA sequencing was also performed in untreated (proliferative) cells at days 0 and 7.
Published in
Fatty acid synthesis therapy-induced senescence (FASTIS) in cancer cells
Verdura S, Llop-Hernández À, Van der Steen T et al. · Cell death & disease 2026 · PMID 42309995 · doi:10.1038/s41419-026-08992-8
This dataset
Open GSE292003 in finder → Find more human RNA-seq datasets →
Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓
2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE292003_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓
3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1236311 and SRA study SRP570480. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗ Paper (PMID 42309995) ↗
Study design
8 conditions, mostly in triplicate
SKBr3 cells, alisertib 500 nmol/L, refeed day… ×3 SKBr3 cells, bleomycin 10 umol/L, refeed day … ×3 SKBr3 cells, proliferative control, ×3 SKBr3 cells, control cells, day 7, ×3 SKBr3 cells, Doxorubicin 10 nmol/L, refeed da… ×3 SKBr3 cells, ND-646 250 nmol/L, refeed day 3,… ×3 SKBr3 cells, Palboclib 1 umol/L, refeed day 3… ×3 SKBr3 cells, TVB-3166 250 nmol/L, refeed day … ×3

Supports a between-group comparison across 24 samples.

How we read this: 8 replicated groups read from 24 sample titles; they account for 24 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.

Samples in this study
Datasets on a similar topic

Search all human RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.